id: NEW:baclofen_tailored_dosing_to_alcohol_use_disorder
name: Baclofen Tailored Dosing for Alcohol Use Disorder â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:baclofen_tailored_dosing
  node_name: Baclofen Tailored Dosing for Alcohol Use Disorder
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Tailored baclofen prescribing involves individualized dose titration based on patient response
  rather than fixed dosing protocols'
- 'Step 2: Variable doses (low to high depending on individual) effectively suppress alcohol cravings
  in AUD patients'
- 'Step 3: Suppression of cravings reduces compulsive alcohol-seeking behavior and consumption'
- 'Step 4: Sustained treatment with appropriate monitoring leads to improved AUD outcomes and potential
  remission'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'R. de Beaurepaire and Philippe Jaury 2024. "Baclofen in the treatment of alcohol
    use disorder: tailored doses matter." https://doi.org/10.1093/alcalc/agad090'
  supporting_citations:
  - Additional citations require full-text access - abstract references RCTs using tailored baclofen doses
  - Additional citations require full-text access - abstract references observational studies with tailored
    dosing
  - Additional citations require full-text access - abstract references meta-analyses of baclofen treatment
  doi: 10.1093/alcalc/agad090
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Tailored baclofen dosing, where physicians adjust doses individually rather than using fixed
  protocols, shows effectiveness in treating alcohol use disorder. The required dose to suppress cravings
  is highly variable between patients (low or high depending on case), necessitating individualized approaches.
  Observational studies using tailored doses consistently show good effectiveness, while RCT evidence
  is encouraging according to certain meta-analyses.
spatial_variation:
  varies_by_geography: true
  variation_notes: Paper specifically notes French context where baclofen is approved without dose limitation,
    making French physicians more likely to use high doses with tailored prescribing
moderators:
- name: physician_prescribing_skills
  direction: strengthens
  strength: strong
  description: Prescription skills, seriousness, and availability of prescribing physicians are of major
    importance in managing tailored baclofen treatment
- name: patient_education
  direction: strengthens
  strength: strong
  description: Patient education about treatment is identified as critical for successful tailored dosing
    outcomes
- name: treatment_monitoring
  direction: strengthens
  strength: strong
  description: Appropriate treatment monitoring prevents severe adverse effects and improves effectiveness
structural_competency:
  equity_implications: This mechanism highlights healthcare system factors that determine treatment access
    and quality. The approval of baclofen without dose limitation in France represents a policy-level
    structural factor that enables tailored prescribing. The emphasis on physician training, availability,
    and monitoring capacity reflects healthcare infrastructure determinants that shape treatment outcomes.
    Structural barriers to accessing physicians with appropriate prescribing skills may create inequitable
    access to effective AUD treatment.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.723356'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
